BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16141201)

  • 1. Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor.
    Song LN; Gelmann EP
    J Biol Chem; 2005 Nov; 280(45):37853-67. PubMed ID: 16141201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription.
    Song LN; Herrell R; Byers S; Shah S; Wilson EM; Gelmann EP
    Mol Cell Biol; 2003 Mar; 23(5):1674-87. PubMed ID: 12588987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways.
    Li H; Kim JH; Koh SS; Stallcup MR
    J Biol Chem; 2004 Feb; 279(6):4212-20. PubMed ID: 14638683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1.
    Yang CK; Kim JH; Li H; Stallcup MR
    J Biol Chem; 2006 Feb; 281(6):3389-97. PubMed ID: 16344550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2).
    Berrevoets CA; Doesburg P; Steketee K; Trapman J; Brinkmann AO
    Mol Endocrinol; 1998 Aug; 12(8):1172-83. PubMed ID: 9717843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer.
    Gregory CW; Fei X; Ponguta LA; He B; Bill HM; French FS; Wilson EM
    J Biol Chem; 2004 Feb; 279(8):7119-30. PubMed ID: 14662770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of the N-terminal region of coactivator TIF2 to the intrinsically disordered AF1 domain of the glucocorticoid receptor is accompanied by conformational reorganizations.
    Khan SH; Awasthi S; Guo C; Goswami D; Ling J; Griffin PR; Simons SS; Kumar R
    J Biol Chem; 2012 Dec; 287(53):44546-60. PubMed ID: 23132854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2).
    Lim J; Ghadessy FJ; Abdullah AA; Pinsky L; Trifiro M; Yong EL
    Mol Endocrinol; 2000 Aug; 14(8):1187-97. PubMed ID: 10935543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
    Wong HY; Hoogerbrugge JW; Pang KL; van Leeuwen M; van Royen ME; Molier M; Berrevoets CA; Dooijes D; Dubbink HJ; van de Wijngaart DJ; Wolffenbuttel KP; Trapman J; Kleijer WJ; Drop SL; Grootegoed JA; Brinkmann AO
    Mol Cell Endocrinol; 2008 Sep; 292(1-2):69-78. PubMed ID: 18656523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
    Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4.
    Amir AL; Barua M; McKnight NC; Cheng S; Yuan X; Balk SP
    J Biol Chem; 2003 Aug; 278(33):30828-34. PubMed ID: 12799378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional intermediary factor 1alpha mediates physical interaction and functional synergy between the coactivator-associated arginine methyltransferase 1 and glucocorticoid receptor-interacting protein 1 nuclear receptor coactivators.
    Teyssier C; Ou CY; Khetchoumian K; Losson R; Stallcup MR
    Mol Endocrinol; 2006 Jun; 20(6):1276-86. PubMed ID: 16322096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities.
    Ding XF; Anderson CM; Ma H; Hong H; Uht RM; Kushner PJ; Stallcup MR
    Mol Endocrinol; 1998 Feb; 12(2):302-13. PubMed ID: 9482670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction.
    Chen SY; Wulf G; Zhou XZ; Rubin MA; Lu KP; Balk SP
    Mol Cell Biol; 2006 Feb; 26(3):929-39. PubMed ID: 16428447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.
    Shen HC; Buchanan G; Butler LM; Prescott J; Henderson M; Tilley WD; Coetzee GA
    Biol Chem; 2005 Jan; 386(1):69-74. PubMed ID: 15843149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and Transcription Intermediary Factor 2 Protein-Protein Interactions.
    Hua Y; Camarco DP; Strock CJ; Johnston PA
    Methods Mol Biol; 2018; 1683():211-227. PubMed ID: 29082495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.
    Fancher AT; Hua Y; Close DA; Xu W; McDermott LA; Strock CJ; Santiago U; Camacho CJ; Johnston PA
    SLAS Discov; 2023 Oct; 28(7):325-343. PubMed ID: 37549772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators.
    Askew EB; Bai S; Hnat AT; Minges JT; Wilson EM
    J Biol Chem; 2009 Dec; 284(50):34793-808. PubMed ID: 19828458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.
    Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2016 Oct; 14(8):453-477. PubMed ID: 27606620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors.
    Slagsvold T; Kraus I; Bentzen T; Palvimo J; Saatcioglu F
    Mol Endocrinol; 2000 Oct; 14(10):1603-17. PubMed ID: 11043576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.